Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial

NCT00227695 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00227695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00227695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Completed
Start date
June 8, 2004
Completion date
December 19, 2017
Enrollment
270 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma